pp-254 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Chronic spontaneous urticaria and asthma / Clinical stage: Phase 2/3 / Modality: Monoclonal antibody (anti-IgE) / Mechanism & Target: IgE antagonism for allergic disease control / Route & form: Intravenous or subcutaneous injection / Differentiation: Long-acting anti-IgE mAb with quarterly dosing potential vs omalizumab
Manufacturer #22188
Founded in 1999, this diversified pharmaceutical group has over two decades of R&D and multi-platform manufacturing expertise in small molecules and biologics. Rx portfolio targets oncology, metabolic, and cardiovascular diseases in solid, injectable, and biologic dosage forms. Advances innovative candidates through global licensing partnerships with multinational pharmaceutical companies.
Manufacturer usually replies in 13 days
None